Literature DB >> 18834404

The role of metastasis suppressor genes in metastatic dormancy.

Christine E Horak1, Jong Heun Lee, Jean-Claude Marshall, S Martin Shreeve, Patricia S Steeg.   

Abstract

Metastasis suppressor genes (MSGs) are defined by their ability to inhibit overt metastasis in a secondary organ without affecting tumor growth at the primary site. Over 20 MSGs have been confirmed in vivo. This class of genes is only unified by their capacity to suppress metastasis, as they encode for proteins with a wide range of biochemical activities that are components of a variety of signaling pathways. In addition, metastasis suppressors impinge upon different stages of the metastatic cascade to manifest their suppressive effects. The MSGs KISS1, KAI1, MKK4/7 and Nm23-H1 promote tumor dormancy at the metastatic site, since tumor cells with induced expression of these MSGs disseminate, but do not form overt metastases in the secondary organ throughout the duration of a metastasis assay. Evidence suggests that KISS1 triggers dormancy in solitary, metastatic tumor cells by causing growth arrest of solitary cells at the secondary site. KAI1 induces growth arrest prior to extravasation by binding a vascular endothelial cell surface marker. MKK4, MKK7 and Nm23-H1 appear to promote dormancy of micrometastatic colonies, after disseminated tumor cells have undergone several rounds of proliferation. Other MSGs may also function in tumor dormancy, but so far their role has not been fully elucidated. Therapeutic approaches that either mimic the effects of MSGs or re-establish MSG expression in metastatic lesions may hold promise for the establishment or maintenance of dormancy.

Entities:  

Mesh:

Year:  2008        PMID: 18834404      PMCID: PMC3508681          DOI: 10.1111/j.1600-0463.2008.01213.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  106 in total

1.  Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

Authors:  Christine E Horak; Jong Heun Lee; Abdel G Elkahloun; Mathieu Boissan; Sylvie Dumont; Tara K Maga; Sandrine Arnaud-Dabernat; Diane Palmieri; William G Stetler-Stevenson; Marie-Lise Lacombe; Paul S Meltzer; Patricia S Steeg
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.

Authors:  S Braun; C Kentenich; W Janni; F Hepp; J de Waal; F Willgeroth; H Sommer; K Pantel
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.

Authors:  B A Yoshida; Z Dubauskas; M A Chekmareva; T R Christiano; W M Stadler; C W Rinker-Schaeffer
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

4.  Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis.

Authors:  S Rodrigues; O De Wever; E Bruyneel; R J Rooney; C Gespach
Journal:  Oncogene       Date:  2007-03-05       Impact factor: 9.867

5.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 6.  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.

Authors:  Jonathan C M Clark; David M Thomas; Peter F M Choong; Crispin R Dass
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 7.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.

Authors:  Lisam Shanjukumar Singh; Michael Berk; Rhonda Oates; Zhenwen Zhao; Haiyan Tan; Ying Jiang; Aimin Zhou; Kashif Kirmani; Rosemary Steinmetz; Daniel Lindner; Yan Xu
Journal:  J Natl Cancer Inst       Date:  2007-08-28       Impact factor: 13.506

9.  Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.

Authors:  Christine E Horak; Arnulfo Mendoza; Eleazar Vega-Valle; Mary Albaugh; Cari Graff-Cherry; William G McDermott; Emily Hua; Maria J Merino; Seth M Steinberg; Chand Khanna; Patricia S Steeg
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration.

Authors:  Miho Takahashi; Tsuyoshi Sugiura; Masakazu Abe; Koutaro Ishii; Kanemitsu Shirasuna
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

View more
  45 in total

1.  Regulation of Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhiqiang Qin; Lu Dai; Bryan Toole; Erle Robertson; Chris Parsons
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Tumor metastasis: moving new biological insights into the clinic.

Authors:  Liling Wan; Klaus Pantel; Yibin Kang
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State.

Authors:  Masoud H Manjili
Journal:  Cancer Res       Date:  2017-05-15       Impact factor: 12.701

4.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 5.  Oncogenic Epstein-Barr virus recruits Nm23-H1 to regulate chromatin modifiers.

Authors:  Saurabh Pandey; Erle S Robertson
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

6.  RCAN1-4 is a thyroid cancer growth and metastasis suppressor.

Authors:  Chaojie Wang; Motoyasu Saji; Steven E Justiniano; Adlina Mohd Yusof; Xiaoli Zhang; Lianbo Yu; Soledad Fernández; Paul Wakely; Krista La Perle; Hiroshi Nakanishi; Neal Pohlman; Matthew D Ringel
Journal:  JCI Insight       Date:  2017-03-09

7.  Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes.

Authors:  Kimberly Long; Toaa Abuelenen; Libia Pava; Maya Bastille; George Blanck
Journal:  Genes Cancer       Date:  2011-10

Review 8.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

9.  Linking metastasis suppression with metastamiR regulation.

Authors:  Mick D Edmonds; Douglas R Hurst; Danny R Welch
Journal:  Cell Cycle       Date:  2009-09-23       Impact factor: 4.534

Review 10.  Dormancy in breast cancer.

Authors:  Malgorzata Banys; Andreas D Hartkopf; Natalia Krawczyk; Tatjana Kaiser; Franziska Meier-Stiegen; Tanja Fehm; Hans Neubauer
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.